Chemistry:LSD-Quinoline

From HandWiki

LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E. Olson and colleagues. It acts as a moderately selective serotonin receptor agonist, primarily at the serotonin 5-HT2A receptor, though its activity at other subtypes such as the 5-HT2B and 5-HT2C receptors, and at other targets of LSD such as dopamine receptors, has not been published. It was developed in the course of resarch into non-hallucinogenic psychoplastogens, and is described as having around 24x lower potency than LSD and with "reduced hallucinogenic potential", though this would suggest it may still be of a similar potency to many psychedelic tryptamine derivatives. It has been researched for therapeutic applications including as a potential antidepressant. LSD-Quinoline was first described in the scientific literature by 2026.[1][2]

See also

  • Substituted lysergamide § Related compounds
  • JRT (drug)
  • Mefloquine

References

  1. ↑ "Skeletal editing by iron-catalyzed carbene insertion of trichloromethanes". Chem 12 (8). August 2026. doi:10.1016/j.chempr.2026.102968. PMID 42677223. PMC 13528700. https://www.cell.com/cms/10.1016/j.chempr.2026.102968/attachment/05fe986a-30b0-496c-9a31-bf111bc63659/mmc2.pdf. 
  2. ↑ "Deconstruction of lysergic acid diethylamide". Proceedings of the National Academy of Sciences of the United States of America 123 (38). September 2026. doi:10.1073/pnas.2603412123. PMID 42709856.